 |
 |
 |
 |
 |
 |
 |
 |
 |
The University of Michigan Scleroderma Program was organized in 2004 in the Division of Rheumatology,
Department of Internal Medicine at the University of Michigan Medical School.
Scleroderma is an inherently complex disease which is best addressed by a multidisciplinary team approach to
treatment and research. The University of Michigan Medical School is one of the leading research institutions in
the world. Its clinical and scientific assets are extensive, cutting edge and uniquely suited to the needs of the
scleroderma community.
The goals of the Scleroderma Program are to develop effective therapies for scleroderma and its complications
and to research the causes and mechanisms of disease. It is only through enhanced understanding of disease
process that a cure will be possible.
Based in the Division of Rheumatology, faculty from many disciplines, including Pulmonary Medicine, the
Pulmonary Hypertension Program of the Division of Cardiology, Pediatric Rheumatology, the Department of
Dermatology, the Division of Hand Surgery, the Department of Occupational Therapy; and the University of
Michigan Cancer Center, currently participate in Program activities.
The Scleroderma Program provides clinical care, primarily on a consultative basis to patients from Michigan and
the Midwest, but also serves as an international referral center.
Program activities include development and performance of complex trials designed to improve the quality of life
and extend survival. Crucial to this enterprise is refined investigation of the science of outcome measures, which in
turn, leads to more robustly designed clinical trials for the future. An effective and talented team has been
assembled and a broad portfolio of research is in progress.
Increasing focus is on initiatives in research into the cause and pathobiology of scleroderma. Basic scientists are
active at the University of Michigan in areas of direct relevance to scleroderma including the biology of fibrosis,
vascular biology, and basic cellular immunology.
The Scleroderma Program at the University of Michigan is dedicated to advancing research and improving care for
patients with scleroderma and related diseases.
For more information, please call 734-763-3110 or visit our website:
Department of Internal Medicine at the University of Michigan Medical School.
Scleroderma is an inherently complex disease which is best addressed by a multidisciplinary team approach to
treatment and research. The University of Michigan Medical School is one of the leading research institutions in
the world. Its clinical and scientific assets are extensive, cutting edge and uniquely suited to the needs of the
scleroderma community.
The goals of the Scleroderma Program are to develop effective therapies for scleroderma and its complications
and to research the causes and mechanisms of disease. It is only through enhanced understanding of disease
process that a cure will be possible.
Based in the Division of Rheumatology, faculty from many disciplines, including Pulmonary Medicine, the
Pulmonary Hypertension Program of the Division of Cardiology, Pediatric Rheumatology, the Department of
Dermatology, the Division of Hand Surgery, the Department of Occupational Therapy; and the University of
Michigan Cancer Center, currently participate in Program activities.
The Scleroderma Program provides clinical care, primarily on a consultative basis to patients from Michigan and
the Midwest, but also serves as an international referral center.
Program activities include development and performance of complex trials designed to improve the quality of life
and extend survival. Crucial to this enterprise is refined investigation of the science of outcome measures, which in
turn, leads to more robustly designed clinical trials for the future. An effective and talented team has been
assembled and a broad portfolio of research is in progress.
Increasing focus is on initiatives in research into the cause and pathobiology of scleroderma. Basic scientists are
active at the University of Michigan in areas of direct relevance to scleroderma including the biology of fibrosis,
vascular biology, and basic cellular immunology.
The Scleroderma Program at the University of Michigan is dedicated to advancing research and improving care for
patients with scleroderma and related diseases.
For more information, please call 734-763-3110 or visit our website:
